Robert Brown, MD
Hepatology · New York, NYNPI 1396782629
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $602,774 of the $967,027 with a category attached, or 62.3%. 20 manufacturers reported payments, led by Gilead at 26.4% of the total. Among hepatology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 676 payments — averaging $1430.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$255K
- Intercept Pharmaceuticals, Inc.$183K
- Mallinckrodt Hospital Products Inc.$151K
- AbbVie$147K
- Madrigal Pharmaceuticals$71K
- Shionogi Inc$33K
- plus $128K from 14 others
Across 30 payments — averaging $37,124 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.1M
- Bausch Health US, LLC$44K
- Pfizer$11K
- Mallinckrodt Enterprises LLC$2K
What the payments were for
- Consulting fees$299,44831%
- Speaking & faculty fees$602,77462%
- Travel & lodging$48,6995%
- Food & beverage$16,0922%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 257 | $255,035 |
| Intercept Pharmaceuticals, Inc. | 78 | $182,986 |
| Mallinckrodt Hospital Products Inc. | 61 | $150,971 |
| AbbVie | 141 | $146,530 |
| Madrigal Pharmaceuticals | 34 | $70,514 |
| Shionogi Inc | 18 | $32,642 |
| Ipsen Biopharmaceuticals, Inc | 10 | $27,080 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $23,444 |
| Mirum Pharmaceuticals, Inc. | 21 | $22,302 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $13,921 |
| Dova Pharmaceuticals | 8 | $12,085 |
| Bausch Health US, LLC | 4 | $9,552 |
| AstraZeneca(2 entities) | 3 | $7,641 |
| Albireo Pharma, Inc. | 1 | $4,550 |
| GSK | 5 | $4,149 |
| Genentech USA, Inc. | 1 | $2,625 |
| Regeneron | 1 | $891 |
| Mallinckrodt Enterprises LLC | 1 | $73 |
| Evoke Pharma, Inc. | 1 | $25 |
| Braintree Laboratories, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$967,027 in reported general payments places this provider in the 95th percentile of 29 hepatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tacrolimus | 11 | $1,240 |
| Carvedilol | 13 | $79 |
| Rosuvastatin Calcium | 13 | $62 |
Paid to pharmacies, not to this prescriber.
Other hepatology in New York
- Douglas DieterichNew York$830K
- Arun JesudianNew York$828K
- Albert MinNew York$277K
- Meena BansalNew York$208K
- Tatyana KushnerNew York$181K
- Howard WormanNew York$119K
- Augusto Villanueva RodriguezNew York$33K
- Jawad AhmadNew York$30K
- Joseph OdinNew York$18K
- Jennifer LeongNew York$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.